CX3CL1 Mimetic Peptide to Disrupt Fractalkine Signaling Dysregulation
Curated pathway from expert analysis
flowchart TD
A["CX3CL1 Fractalkine<br/>Neuron-derived ligand"]
B["CX3CR1 Receptor<br/>Microglial surface"]
C["PI3K/Akt Signaling<br/>Survival pathway activation"]
D["Microglial Surveillance<br/>Homeostatic state maintenance"]
E["Synaptic Protection<br/>Reduced excitotoxicity"]
F["Amyloid Plaque<br/>Microglial Clearing"]
G["CX3CL1 Mimetic Peptide<br/>Therapeutic intervention"]
H["Tau Pathology Reduction<br/>AD progression slowing"]
A --> B
B --> C
C --> D
D --> E
D --> F
E --> H
F --> H
G -->|"activates"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for CX3CL1 yet. Search RCSB →
Median TPM across 13 brain regions for CX3CL1/CX3CR1 axis; target: CX3CR1 receptor activation from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CX3CL1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF C57BL/6 mice with established high-fat diet-induced atherosclerosis (12 weeks of HFD) receive daily intraperitoneal CX3CL1 mimetic peptide (10 mg/kg) for 8 weeks, THEN aortic root plaque area will | Reduction in atherosclerotic plaque burden and systemic inflammatory markers | — no observation — | pending | 0.65 |
| IF primary human macrophages are pre-treated with CX3CL1 mimetic peptide (1 μM) for 30 minutes before stimulation with oxLDL (50 μg/mL), THEN CX3CR1 surface internalization will increase by ≥40% and d | Disruption of CX3CR1-mediated pro-inflammatory signaling in human macrophages | — no observation — | pending | 0.70 |